Biohaven

NYSE: BHVN ↗$14.05 USD~$1.5B MCAP

#Neurology #Neuroscience #Rare Disease #Migraine

Biohaven is a clinical-stage biopharmaceutical company developing therapies for neurological and neuropsychiatric diseases. Following the spin-off of its commercial migraine portfolio to Pfizer, Biohaven is advancing next-generation neuroscience programs including IGF-1 targeted therapies and rare disease programs.

Company Info

Sector:Neuroscience / Neurology

Headquarters:New Haven, Connecticut, USA

Founded:2014

Website:www.biohaven.com/

Upcoming Milestones & Key Dates

2026-Q4

Clinical

BHV-7000 Phase 3 topline data in focal epilepsy

2026-Q3

Corporate

Scientific leadership transition (per ARPA-H/biohaven news)

Clinical Development Pipeline

BHV-7000

Target: Kv7.2/7.3 activator

Focal epilepsy / bipolar disorder

Preclinical

Phase 1

Phase 2

Phase 3

Approved

BHV-8000

Target: TYK2/JAK1

Early Parkinson's disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Taldefgrobep alfa

Target: Myostatin

Spinal muscular atrophy

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership ↗

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

Leadership Team

Vlad Coric, MD

Chairman & CEO

Matthew Buten

Chief Financial Officer

Irfan Qureshi, MD

Chief Medical Officer

Careers & Job Openings

See all open roles

Multiple Departments

New Haven, Connecticut, USA

Apply Now →